In Silico Study of L-mimosine Compounds in Putri Malu Herba (Mimosa pudica L.) which has the potential as a candidate for Sars-CoV-2 Antivirus

Abstract

Coronavirus disease 2019 (COVID-19) is a new infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Putri malu herb (Mimosa pudica L.) contains L-mimosine compound which has various activities including inhibition of cell proliferation and tumor growth in vivo and has the potential to be developed as an antiviral because it is known to have activity as an antiviral for mumps based on previous research. This study aims to determine the antiviral potential of the L-mimosine compound in the Putri malu herb (Mimosa pudica L.) in inhibiting the Sars-CoV-2 receptor through an in silico study using the molecular docking method. The results show that L-mimosine has the ability as a protein inhibitor of the main protease receptor (PDB ID: 7JKV) in the presence of hydrogen bonds with amino acid residues, but with a weak binding energy or binding energy affinity compared to the native ligand, which is -5.72 kcal/mol